Sun Pharma Advanced Research Co. has told NDTV Profit that it expects no financial impact or need for fresh capital expenditure following the discontinuation of SCD-044 trials, with other pipeline ...

SPARC share price plunged 20% following poor Phase 2 trial outcomes for SCD-044. The stock peaked at ₹186 but fell to ₹156.50 ...

This Small-cap Pharma Stock, engaged in the research and development of innovative pharmaceutical products, focusing on therapies for unmet medical needs, hit a 20 percent lower circuit after the ...

SPARC and its partner Sun Pharma said they will "evaluate the appropriate next steps", but the setback sent its shares tumbling nearly 18% on the BSE on Wednesday.

Sun Pharma Advanced Research Company (SPARC) dropped 18.63% to Rs 159.15 after the company announced disappointing results from a key clinical trial.

Shares of Sun Pharma Advanced Research Company Ltd (SPARC) plunged nearly 20% on Wednesday on the NSE, after the company ...

The shares of Sun Pharma Advanced Research Company (SPARC) fell over 18 per cent on Wednesday, on BSE, on the announcement ...

Sun Pharma Advanced Research Company (SPARC) psoriasis drug, Vibozilimod (SCD-044), failed to meet primary endpoints in Phase ...

Sun Pharma Advanced Research Company (SPARC) shares plummeted nearly 20% after its psoriasis drug, SCD-044, failed to meet primary endpoints in Phase 2 trials.

Sun Pharma disclosed that the drug did not meet primary endpoints in either study and as a result, the development of the SCD ...

Shares of Sun Pharma Advanced Research Company (SPARC) shares crashed significantly on Wednesday after the company announced ...

Shares of Sun Pharma Advanced Research Company (SPARC), the research division of India’s largest pharmaceutical firm Sun Pharma, fell 19 per cent to Rs 158 each after unsatisfactory Phase 2 trial ...